Replies to post #163702 on Biotech Values

[DewDiligence]

(ENTA)—NVS’ 2Q13 PR* (p24) says the partial clinical hold on DEB025 has been “revised” and a DDI study has been started. The revision was presumably the FDA’s permission to conduct the DDI study, and I’m guessing that the second drug in the DDI study is ENTA’s EDP-239. (ENTA is +3% today.)

*http://www.novartis.com/cs/www.novartis.com-v4/downloads/investors/financial-results/quarterly-results/2013-07-interim-financial-report-en.pdf